Gilead Sciences (United Kingdom)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United Kingdom), United Kingdom, covering academic research published from 2001 to 2023. Read More.
Open Access Percentage
75%
Total
Publications
223
Total Open
Publications
168
Total
Citations
4.8K
Open Access
Percentage
75%
Total
Publications
223
Total Open
Publications
168
Total
Citations
4.8K
Breakdown
Publisher Open
38%
Both
29%
Other Platform Open
8%
Closed
25%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 33%
49
Hybrid 37%
56
No Guarantees 30%
45
Other Platform Open
Domain 86%
71
Institution 34%
28
Other Internet 10%
8
Preprint 8%
7
Public 4%
3
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 71 |
Europe PMC | Domain | 28 |
Research Square | Preprint | 4 |
Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes | Institution | 4 |
University of Milano-Bicocca - BOA - Bicocca Open Archive | Institution | 3 |
University of Bristol - Bristol Research | Institution | 3 |
Semantic Scholar | Public | 3 |
University of Oxford - Oxford University Research Archive (ORA) | Institution | 2 |
University College London - UCL Discovery | Institution | 2 |
Universitat Pompeu Fabra - Repositori digital de la UPF | Institution | 2 |